Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Clinical and Electrophysiological Heterogeneity in Adult Charcot-Marie-Tooth Disease

13 listopada 2026 zaktualizowane przez: Centre Hospitalier Universitaire de Nice

Clinical and Electrophysiological Heterogeneity in Adult Charcot-Marie-Tooth Disease: An Observational Study of the Relationships Between CMTES-v2, Nerve Conduction Parameters, and Functional Capacity

CMT-PROFILE is a single-center, cross-sectional observational study involving adults with Charcot-Marie-Tooth disease (CMT). The study will investigate the association between clinical disease severity, measured using the CMT Examination Score version 2 (CMTES-v2), and motor electrophysiological parameters, including compound muscle action potential (CMAP) amplitudes and motor nerve conduction velocities. Secondary objectives include characterizing clinical-electrophysiological concordance, comparing functional capacity, muscle strength and mobility across concordance groups, and exploring demographic, clinical, biological and genetic factors associated with variability in disease expression. Approximately 250 patients are planned for inclusion. All assessments will be performed at a single reference time point (M0), with no longitudinal follow-up.

Przegląd badań

Status

Jeszcze nie rekrutacja

Interwencja / Leczenie

Typ studiów

Obserwacyjny

Zapisy (Szacowany)

250

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Kontakt w sprawie studiów

Kopia zapasowa kontaktu do badania

Lokalizacje studiów

    • Alpes Maritimes
      • Nice, Alpes Maritimes, Francja, 06000

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

18 lat i starsze (Dorosły, Starszy dorosły)

Akceptuje zdrowych ochotników

Nie

Płeć kwalifikująca się do nauki

Wszystko

Metoda próbkowania

Próbka bez prawdopodobieństwa

Badana populacja

Adults with Charcot-Marie-Tooth disease evaluated at the Peripheral Neuromuscular Rare Disease Reference Center of Nice University Hospital. The study aims to characterize the relationships between clinical disease severity, assessed using the CMTES-v2, motor electrophysiological parameters, and functional capacity. Participants will undergo a single reference assessment (M0), with no subsequent follow-up. The planned sample size is approximately 250 participants, subject to confirmation against the approved protocol.

Opis

Inclusion Criteria:

  • Adults aged 18 years or older.
  • Diagnosis of peripheral sensory polyneuropathy.
  • Classification as length-dependent (LDN) or non-length-dependent (NLDN) based on clinical and electrophysiological findings.
  • Available nerve conduction study including sural and radial sensory nerve amplitudes allowing calculation of the SRAR.
  • Evaluated at the Peripheral Neuromuscular Rare Disease Reference Center, Nice University Hospital, between January 2013 and July 2026.

Exclusion Criteria:

  • Missing or incomplete clinical or electrophysiological data preventing SRAR calculation.
  • Unclassifiable neuropathy phenotype.
  • Technical factors affecting the reliability of nerve conduction studies.

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Modele obserwacyjne: COHORT
  • Perspektywy czasowe: CROSS_SECTIONAL

Kohorty i interwencje

Grupa / Kohorta
Interwencja / Leczenie
Adults with Charcot-Marie-Tooth Disease

This observational, cross-sectional study evaluates clinical severity, electrophysiological parameters, and functional capacity in adults with Charcot-Marie-Tooth disease (CMT). Data collected at a single reference time point (M0) include the CMT Examination Score version 2 (CMTES-v2), nerve conduction study parameters, including compound muscle action potential (CMAP) amplitudes and motor nerve conduction velocities, and available functional and clinical measures. Additional variables may include muscle strength, mobility, pain, patient-perceived disease severity, occupational impact, and demographic, clinical, and genetic characteristics, as specified in the study protocol. No study-specific treatment or intervention is administered. There is no longitudinal follow-up

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Association Between CMTES-v2 and Motor Electrophysiological Parameters
Ramy czasowe: At day 0 (single assessment; no follow-up).

To assess the association between the CMTES-v2 total score and prespecified motor electrophysiological parameters, including distal CMAP amplitudes and motor nerve conduction velocities, using correlation analyses as specified in the statistical analysis plan.

At day 0 (single assessment; no follow-up).

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Clinical-Electrophysiological Concordance and Discordance Classification
Ramy czasowe: At Day 0 (single assessment; no follow-up).

disease severity and electrophysiological impairment, using standardized residuals derived from the difference between observed CMTES-v2 scores and scores predicted from motor electrophysiological parameters, divided by the residual standard deviation. Patients will be classified into three mutually exclusive categories: concordant (standardized residual between -1.96 and +1.96), greater clinical severity than predicted (standardized residual above +1.96), or lower clinical severity than predicted (standardized residual below -1.96). Results will be expressed as the number and percentage of patients in each category.

At Day 0 (single assessment; no follow-up).
Age at Assessment Across Clinical-Electrophysiological Concordance Groups
Ramy czasowe: At Day 0 (single assessment; no follow-up)

To investigate whether age at clinical assessment differs according to the degree of clinical-electrophysiological concordance, age will be recorded in years and compared across the three predefined concordance groups.

At Day 0 (single assessment; no follow-up)
Age at Symptom Onset Across Clinical-Electrophysiological Concordance Groups
Ramy czasowe: At Day 0 (single assessment; no follow-up)

To investigate whether age at clinical assessment differs according to the degree of clinical-electrophysiological concordance, age will be recorded in years and compared across the three predefined concordance groups.

At Day 0 (single assessment; no follow-up)
Disease Duration Across Clinical-Electrophysiological Concordance Groups
Ramy czasowe: At Day 0 (single assessment; no follow-up)

To evaluate the relationship between disease duration and clinical-electrophysiological concordance, disease duration will be calculated as the interval, expressed in years, between the reported onset of symptoms and the reference clinical assessment. Disease duration will be compared across the three predefined concordance groups.

At Day 0 (single assessment; no follow-up)
Genetic Subtype Distribution Across Clinical-Electrophysiological Concordance Groups
Ramy czasowe: At Day 0 (single assessment; no follow-up)

To investigate whether the distribution of genetically confirmed Charcot-Marie-Tooth disease subtypes differs according to clinical-electrophysiological concordance, genetic subtypes documented in the medical records will be categorized and compared across the three predefined concordance groups. Results will be reported as the number and percentage of patients within each genetic subtype among those with available genetic data.

At Day 0 (single assessment; no follow-up)
Functional Performance Across Clinical-Electrophysiological Concordance Groups (CMT-FOM)
Ramy czasowe: At Day 0 (single assessment; no follow-up).

To evaluate whether functional performance differs according to clinical-electrophysiological concordance, functional capacity will be quantified using the total score of the Charcot-Marie-Tooth Functional Outcome Measure (CMT-FOM). Scores will be compared across the three predefined concordance groups among patients with available assessments.

At Day 0 (single assessment; no follow-up).
Muscle Strength Across Clinical-Electrophysiological Concordance Groups (MRC Scale)
Ramy czasowe: At Day 0 (single assessment; no follow-up)

To assess differences in muscle strength according to clinical-electrophysiological concordance, muscle strength will be evaluated using the Medical Research Council (MRC) grading scale, ranging from 0 (no visible or palpable muscle contraction) to 5 (normal muscle strength). Recorded muscle strength grades will be compared across the three predefined concordance groups.

At Day 0 (single assessment; no follow-up)
Right Handgrip Strength Across Clinical-Electrophysiological Concordance Groups
Ramy czasowe: At Day 0 (single assessment; no follow-up)

To assess differences in right handgrip strength according to clinical-electrophysiological concordance, right handgrip strength will be measured by dynamometry, with the highest value obtained from three trials retained for analysis. Measurements will be compared across the three predefined concordance groups.

At Day 0 (single assessment; no follow-up)
Left Handgrip Strength Across Clinical-Electrophysiological Concordance Groups
Ramy czasowe: At Day 0 (single assessment; no follow-up).

To assess differences in left handgrip strength according to clinical-electrophysiological concordance, left handgrip strength will be measured by dynamometry, with the highest value obtained from three trials retained for analysis. Measurements will be compared across the three predefined concordance groups.

At Day 0 (single assessment; no follow-up).
Functional Mobility Across Clinical-Electrophysiological Concordance Groups (Timed Up and Go)
Ramy czasowe: At Day 0 (single assessment; no follow-up)

To investigate differences in functional mobility according to clinical-electrophysiological concordance, mobility will be assessed using the Timed Up and Go (TUG) test, measuring the time required to rise from a chair, walk three meters, turn, return to the chair and sit down. Completion time will be recorded in seconds and compared across the three predefined concordance groups. Inability to complete the test safely will be recorded as a non-feasible assessment rather than assigned an arbitrary completion time.

At Day 0 (single assessment; no follow-up)
Pain Intensity Across Clinical-Electrophysiological Concordance Groups
Ramy czasowe: At Day 0 (single assessment; no follow-up).

To investigate whether pain intensity differs according to clinical-electrophysiological concordance, average pain intensity over the preceding seven days will be assessed using an 11-point numerical rating scale, ranging from 0 (no pain) to 10 (worst imaginable pain). Pain scores will be compared across the three predefined concordance groups.

At Day 0 (single assessment; no follow-up).
Patient-Perceived Disease Severity Across Clinical-Electrophysiological Concordance Groups
Ramy czasowe: At Day 0 (single assessment; no follow-up)

To evaluate differences in patient-perceived disease severity according to clinical-electrophysiological concordance, overall disease severity will be self-rated using a five-point ordinal scale ranging from 1 (very mild) to 5 (very severe). Scores will be compared across the three predefined concordance groups.

At Day 0 (single assessment; no follow-up)
Work Absenteeism Across Clinical-Electrophysiological Concordance Groups (WPAI:SHP)
Ramy czasowe: At Day 0 (single assessment; no follow-up)

To investigate differences in work absenteeism associated with Charcot-Marie-Tooth disease according to clinical-electrophysiological concordance, absenteeism will be assessed using the Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI:SHP) and quantified as the percentage of working time missed due to the disease during the preceding seven days, ranging from 0% to 100%. Comparisons will be performed across the three predefined concordance groups among employed participants for whom the measure is applicable.

At Day 0 (single assessment; no follow-up)
Work Presenteeism Across Clinical-Electrophysiological Concordance Groups (WPAI:SHP)
Ramy czasowe: At Day 0 (single assessment; no follow-up).

To investigate differences in work-related productivity impairment while present at work according to clinical-electrophysiological concordance, presenteeism will be assessed using the WPAI:SHP questionnaire and expressed as the percentage of impairment while working attributable to Charcot-Marie-Tooth disease during the preceding seven days, ranging from 0% to 100%. Results will be compared across the three predefined concordance groups among participants for whom the measure is applicable.

At Day 0 (single assessment; no follow-up).
Overall Work Productivity Impairment Across Clinical-Electrophysiological Concordance Groups (WPAI:SHP)
Ramy czasowe: At Day 0 (single assessment; no follow-up).

To assess whether overall work productivity impairment differs according to clinical-electrophysiological concordance, overall impairment will be calculated from the absenteeism and presenteeism components of the WPAI:SHP questionnaire and expressed as a percentage ranging from 0% (no impairment) to 100% (complete impairment) over the preceding seven days. Results will be compared across the three predefined concordance groups among participants for whom the measure is applicable

At Day 0 (single assessment; no follow-up).
Daily Activity Impairment Across Clinical-Electrophysiological Concordance Groups (WPAI:SHP)
Ramy czasowe: At Day 0 (single assessment; no follow-up)

To assess differences in the impact of Charcot-Marie-Tooth disease on usual daily activities according to clinical-electrophysiological concordance, activity impairment will be quantified using the WPAI:SHP questionnaire and expressed as a percentage ranging from 0% (no impairment) to 100% (complete impairment) over the preceding seven days. Results will be compared across the three predefined concordance groups, irrespective of employment status

At Day 0 (single assessment; no follow-up)

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Śledczy

  • Główny śledczy: Angela Puma, Centre Hospitalier Universitaire de Nice

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Szacowany)

1 grudnia 2026

Zakończenie podstawowe (Szacowany)

1 grudnia 2026

Ukończenie studiów (Szacowany)

31 grudnia 2027

Daty rejestracji na studia

Pierwszy przesłany

29 października 2026

Pierwszy przesłany, który spełnia kryteria kontroli jakości

13 listopada 2026

Pierwszy wysłany (Rzeczywisty)

16 listopada 2026

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

16 listopada 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

13 listopada 2026

Ostatnia weryfikacja

1 października 2026

Więcej informacji

Terminy związane z tym badaniem

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Nie

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Subskrybuj